Veracyte, Inc. Veracyte, Inc.

Veracyte, Inc.

VCYT

Classificação em ações #4359
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Preço da ação
$44.93
Última sincronização: 2026-10-20
Valor de mercado
$3.61B
Variação (1 dia)
2.57%
Variação (1 ano)
24.45%
País
US
Negociar Veracyte, Inc. (VCYT)

Categoria

Healthcare
Lucros da Veracyte, Inc. (VCYT)
Lucros em Jun 2026 TTM: $108.94M
De acordo com os últimos relatórios financeiros da Veracyte, Inc., os ganhos atuais da empresa são de $108.94M. Em 2023, a empresa teve ganhos de $-76.61M, uma diminuição em relação a aos ganhos de 2022, que foram de $-36.43M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Veracyte, Inc. de 2011 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $108.94M 323.17%
2024 $25.74M -133.60%
2023 $-76.61M 110.32%
2022 $-36.43M -55.39%
2021 $-81.65M 133.89%
2020 $-34.91M 177.08%
2019 $-12.60M -45.22%
2018 $-23.00M -25.82%
2017 $-31.00M -1.13%
2016 $-31.36M -6.96%
2015 $-33.70M 14.74%
2014 $-29.37M 14.83%
2013 $-25.58M 37.17%
2012 $-18.65M 29.10%
2011 $-14.45M 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$7.61B 6,884.58%
US
$4.76B 4,271.21%
US
$-252.70M -331.96%
US
- -
CN
$1.66B 1,421.94%
US